Good
Mostly Aligned
Patient Risk:
Moderate
Summary
The provided warning theme (pulmonary toxicity, hepatic injury, and worsened arrhythmias/QTc/TdP risk) is supported by the supplied label excerpts (Sections 5.2, 5.3, 5.4) with relevant monitoring and management guidance. However, many additional mechanistic/classification and dosing-profile claims were not evaluated against the supplied label excerpts and are not substantiated by the provided label text.
Category Scores
Accurate Statements
Pacerone can cause pulmonary toxicity and fatal pulmonary toxicity; monitoring (baseline CXR/PFTs and repeat assessment) and consideration of alternative antiarrhythmic therapy are recommended if pulmonary toxicity occurs.
Label Section 5.2 Pulmonary Toxicity
Pacerone can cause life-threatening hepatic injury; baseline and periodic liver transaminase monitoring is recommended; if transaminases exceed 3x normal (or double from elevated baseline) discontinue or reduce dose and obtain follow-up tests.
Label Section 5.3 Hepatic Injury
Pacerone can exacerbate the presenting arrhythmia and can cause serious ventricular arrhythmias; QTc prolongation and Torsade de Pointes risk are discussed; correct hypokalemia/hypomagnesemia/hypocalcemia prior to initiation to reduce TdP risk.
Label Section 5.4 Worsened Arrhythmia
Adverse reactions leading to discontinuation can include pulmonary infiltrates or fibrosis and elevation of liver enzymes, and paroxysmal ventricular tachycardia.
Label Section 6.1 Clinical Trials Experience
Unsupported Statements
Amiodarone is an antiarrhythmic medicine.
Not supported by the supplied label excerpts (Sections 1, 2, 5, 6, 7, 8, 12, 13) provided in the prompt.
Amiodarone belongs to the Vaughan Williams classification as a Class III antiarrhythmic / classified primarily as a Class III antiarrhythmic.
Not supported by the supplied label excerpts.
Amiodarone mainly works by prolonging cardiac repolarization / prolonging repolarization / primary action is prolonging the electrical phase controlling repolarization.
No mechanistic electrophysiology statements substantiating this were included in the supplied label excerpts.
Amiodarone has properties of other antiarrhythmic classes; multi-channel activity; multi-class effects rather than only Class III behavior; broader electrophysiology effects contribute to ability to treat different types of arrhythmias; drugs in Class III are closest class cousins; Class III drugs often prolong repolarization.
Not supported by the supplied label excerpts.
Amiodarone helps stabilize abnormal heart rhythms by prolonging repolarization.
Not supported by the supplied label excerpts.
Amiodarone is used to treat and prevent certain serious cardiac rhythm problems.
The supplied label excerpt only specifies treatment of documented, life-threatening recurrent ventricular fibrillation and life-threatening recurrent hemodynamically unstable tachycardia; 'prevent' and broader phrasing are not supported.
Amiodarone is used particularly where other options are less suitable.
The supplied indication includes use when other available antiarrhythmics have not responded or cannot be tolerated, but this exact phrasing is not directly supported as stated.
Amiodarone is used for rhythm control for atrial and ventricular tachyarrhythmias.
Not supported by the supplied label excerpt for Pacerone indication (ventricular fibrillation and unstable tachycardia).
Amiodarone may be used in emergency settings for refractory unstable or life-threatening rhythms.
Not directly supported by the supplied label excerpt wording ('life-threatening recurrent' and 'not responded to adequate doses of other available antiarrhythmics or when alternative agents cannot be tolerated' is supported, but 'emergency settings' is not).
Amiodarone is not classified as a beta blocker / not classified as a calcium channel blocker.
Not addressed in the supplied label excerpts.
Amiodarone has additional mixed effects / long-term dosing profile.
Not supported by the supplied label excerpts.
Contradictions
Important Omissions
The submitted content did not clearly restrict indication claims to the exact FDA-labeled population/arrhythmias (documented, life-threatening recurrent ventricular fibrillation and life-threatening recurrent hemodynamically unstable tachycardia in adults who have not responded to adequate doses of other available antiarrhythmics or cannot tolerate alternatives).
Importance:
Moderate
Any mention of baseline and periodic monitoring specifics for pulmonary, hepatic, and electrolytes (e.g., diffusion capacity; CXR/PFT cadence; transaminase thresholds; correction of hypokalemia/hypomagnesemia/hypocalcemia) was not consistently and completely tied to the exact label guidance in the provided evaluated claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The warnings about pulmonary toxicity, hepatic injury, and worsened arrhythmias (including QTc/TdP risk and electrolyte correction) align with the label excerpts, which supports safety-relevant content. However, unsupported/overbroad claims about indications (e.g., atrial tachyarrhythmias and 'prevent' and 'emergency settings') and unsupported mechanistic/classification statements could mislead interpretation of appropriate use.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Multiple mechanistic/classification and broader indication claims are not supported by the supplied FDA label excerpts; only the pulmonary/hepatic/cardiac warning theme is well supported.
Suggested Improvement
Limit statements to what is explicitly supported by the provided label sections (especially Sections 1, 5.2-5.4, and 2 for monitoring/electrolyte correction). Remove or qualify unsupported mechanistic/classification and broader indication language not present in the supplied excerpts.